ArticleHepatology international2026
Risk factors of adult recipient survival beyond 20 years since liver transplantation: retrospective cohort study.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thirty Years and Beyond: Long-term Outcomes After Liver Transplantation at a Single Center: Progress, Challenges, and Future Implications.Transplantation direct · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term recipient survival post-liver transplant (LT) has not significantly improved over time due to the presence of deleterious risk factors and multiple complications. We analyzed the causes of death and risk factors of patient survival beyond, at least, a 20-year follow-up.
methodsThis retrospective cohort study comprised 409 adult patients who underwent LT between January 1990 and March 2005. 126 recipient survivors for, at least, a 20-year follow-up, were compared with 283 non-survivors.
resultsMedian age was significantly higher in non-survivors than in survivors (47-year vs 57-year; p < 0.001). Most common indications of LT were alcoholic cirrhosis, HCV or HBV cirrhosis and hepatocellular carcinoma. Intraoperative blood (p = 0.005) and plasma (p = 0.002) transfusion were significantly higher in non-survivors. The rates of hepatic artery thrombosis/stenosis and primary non-function were significantly higher in non-survivors. The median follow-up period of the survivors was 23.7 (20-34.3) years vs 6.2 (0-29.5) years in non-survivors (p < 0.001). A significantly higher incidence of renal insufficiency (p < 0.001) and respiratory complications (p = 0.001) were seen in non-survivors. The commonest causes of death beyond a 20-year follow-up were hepatic failure (33.6%), de novo tumors (22.2%), cardiovascular (18.7%), infection (14.8%), hepatocarcinoma recurrence (2.5%), and pulmonary (2.1%). Patient survival at 20 and 30 years after LT were 37.7%, and 27.3%, respectively. Advanced recipient age, intraoperative blood transfusion and post-LT renal insufficiency were risk factors for recipient survival beyond, at least, 20 years since LT.
conclusionThirty-year patient survival post-LT was 27.3%. Advanced recipient age, intraoperative blood transfusion and post-renal insufficiency were risk factors for survival.
Indexed as
Identifiers
41691104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.